Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWing Fai LiKGKira GritsmanDLDavid Levitz

Discussion

Loading...

Member takes

Overview

Real-world evidence shows low dose HMA-venetoclax improves cost-effectiveness and reduces neutropenia in AML/MDS patients.

Key Points

  • This research compares the cost-effectiveness of low dose versus standard dose HMA-venetoclax in patients with AML/MDS.
  • Analyzed prospective and retrospective cohorts of myeloid malignancies at MECCC.
  • Grouped treatments into standard-dose and metronomic low-dose regimens.
  • Used a Markov model to assess treatment transitions and survival outcomes.
  • Calculated cost-effectiveness ratios using quality-adjusted life years and total cost comparisons.
  • Overall survival between low and standard dose groups was similar (p = 0.066).
  • Monthly treatment costs were $5,269 for low dose versus $19,875 for standard dose.
  • Lifetime healthcare costs were $244,223 for low dose versus $299,038 for standard.
  • Low dose regimen showed significant reduction in neutropenia and fewer hospitalizations.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0echttps://doi.org/10.1182/blood-2025-4429
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML2025
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025
  4. 4Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  5. 5Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial2025 · 2 citations